Uwe SiebertUwe Siebert, MD, MPH, ScD is professor of Public Health, Medical Decision Making, and Health Technology Assessment (HTA), and chair of the Department of Public Health, Health Services Research, and HTA at UMIT TIROL - University for Health Sciences and Technology in Austria. He is also adjunct professor of Epidemiology and Health Policy and Management at the Harvard Chan School of Public Health and affiliated with the Institute for Technology Assessment at the Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Uwe has more than 30 years of experience in medicine and health decision making. After working as a physician in international public health projects in South America, West Africa, and Europe, he earned an MPH at the Munich School of Public Health and was appointed director of the Bavarian Public Health Coordinating Center. He then completed an MSc in Epidemiology and ScD in Health Policy and Management with concentration in Health Decision Sciences at the Harvard School of Public Health and took up a faculty position at Harvard Medical School. From 2012-2021, he was the director of the Division for HTA in the ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is currently Clinical Guideline Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF) and involved in the European Commission’s EUCAPA capacity building for patient representatives under the new EU HTA regulation.

He is recognized for his contributions to translational and causal methods in the framework of healthcare policy advice and HTA as well as in the clinical context of routine healthcare, public health policies, and patient guidance. Leading several international consortium projects, Uwe recently works on the integration of social, patient, equity, and sustainability aspects into the traditional benefit-harm-cost assessment. He gives courses for ISPOR, patient organizations, universities, and industry in Europe, USA, South America, and Asia.

Uwe has served ISPOR as director in the Board of Directors, chair of the 11th Annual European ISPOR Conference in Athens, chair of the Applied HTA Working Group, and co-chair of the ISPOR-SMDM Modeling Good Research Practices Task Force. He is currently a member of the ISPOR Latin America Consortium Advisory Committee, leadership member of the ISPOR Personalized/Precision Medicine Special Interest Group, and the Editorial Advisory Board of Value in Health. He has provided short courses in Decision Modeling, HTA, and Causal Inference from Real-World Data to more than 2000 ISPOR participants.

He was President of the Society for Medical Decision Making (SMDM) and a member of the Harvard Flagship Initiative in Comparative Effectiveness Research, the ‘National HTA Strategy’ Expert Group of the Austrian Federal Ministry of Health, and the International Expert Committee Advising IQWiG.

Uwe has worked with several HTA and regulatory authorities (eg, IQWiG/Germany, NICE/UK, ANVISA/Brazil, AHRQ/USA, CADTH/Canada, LBI-HTA/Austria) and advises public and government agencies, academic institutions, and industry. He has authored more than 400 publications (> 30,000 citations, H index > 80) and is editor of the European Journal of Epidemiology, and member of the editorial board of several scientific journals.

ISPOR Vision Statement by Uwe Siebert

I am honored to be a candidate for President-Elect of ISPOR and, if elected, stand ready to help guide the ISPOR community and leadership in a way that strengthens and expands its mission. With my passion and professional experience in health economics and outcomes research (HEOR) and my dedication and past involvement with ISPOR in the areas of science, education, and policy advice, I feel this is one of the most honorable and beneficial roles I can imagine for my professional life in the years to come, with the goal of improving sustainable access to high-quality and efficient healthcare worldwide.

For me, ISPOR has become the multi- and transdisciplinary scientific home for an ever-growing number of researchers, providers, patient advocates, manufacturers, CROs, data vendors, regulatory bodies, and payers around the globe, providing the largest platform to support healthcare decisions.

Having lived and worked in Europe, South America, West Africa, and North America has helped me develop an international perspective on education, research, and healthcare. And you, the ISPOR community, have given me the opportunity to share my experiences with an amazing international community and to learn from other members. Through my participation in many ISPOR activities, I have gained direct knowledge of ISPOR’s strategies and outreach programs. And as an HTA author and advisor for regulatory and HTA bodies in Germany, UK, Austria, USA, Canada, and Brazil, I have learned to build bridges between scientists and decision makers.

My vision is for ISPOR to be a central player in the transformation of healthcare towards better health for all, advancing its global impact through several key tasks along the ISPOR Strategic Plan Update 2024 and ISPOR’s strategic pillars:

  1. Scientific rigor: Maintain scientific rigor and catalyze innovation through ISPOR’s activities to develop, teach, apply, and disseminate best research practices through conferences, online activities, Signal series, spotlight sessions, special interest groups, task forces, Value in Health, and other ISPOR publications.
  2. Inclusiveness and sustainability: Enhance current approaches to HEOR along ISPOR’s organizational values to fully integrate the “flower of values” and all HTA domains for all stakeholders in an inclusive, diverse, fair, and sustainable way.
  3. Education: Support ISPOR's excellent education team to further develop a mix of face-to-face short courses, workshops and other educational events, and expand web-based formats to reach those unable to attend in-person courses or annual conferences.
  4. Connections: Strengthen connections and exchange of information/ideas between all stakeholders within ISPOR and in collaboration with other scientific societies and networks.
  5. Globalization: In addition to our efforts in Asia-Pacific, Latin America, and Eastern Europe, we must continue to support colleagues, students, and chapters in Africa and the Middle East to unite the forces of HEOR.

With my international network, my dual education in human medicine and health decision science, my interdisciplinary academic background, my experience working with patient representatives and industry, my love of teaching, and my well-established relationships with many government agencies, I believe that I would be an effective President-Elect, and then President, for all members of our wonderful ISPOR community.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now